Intelligent metabolic regulation for consistent weight loss.
Tirzepatide is a dual agonist of GIP and GLP-1 receptors, acting in an integrated way across incretin pathways.It increases insulin secretion in a glucose-dependent manner and improves glycaemic regulation (reducing peaks and variability).
It acts on appetite/satiety centres, helping to reduce food intake and supporting adherence to body recomposition strategies.

Key Benefits

• Significant reduction in body weight in studies involving people with obesity/overweight (results depend on dose, duration, and adherence).
• Robust improvement in glycaemic control (HbA1c) in people with type 2 diabetes, with dose-dependent reductions observed in clinical trials.
• Cardiometabolic improvements associated with weight loss and incretin pathway activity.
• Maintenance of weight loss with continued treatment, demonstrating sustained outcomes when use is maintained within protocol (in maintenance trials).

Mechanism of Action
Retatrutide is a triple agonist of GLP-1, GIP, and glucagon receptors. This combination works in an integrated manner to reduce appetite and increase satiety, improve glycaemic homeostasis, and promote greater energy expenditure/thermogenesis via activity at the glucagon receptor.

Key Benefits
– Marked reduction in body weight in clinical studies, with high-impact results in obesity.
– Improved glycaemic control and cardiometabolic markers (e.g., inflammatory lipids and blood pressure reported in readouts).
– Reduction in liver fat and improvements associated with metabolic liver disease (MASLD/MASH) in a Phase 2a study.
– Quality of weight loss (body composition): evidence suggests a greater reduction in fat mass, without a disproportionate increase in lean mass loss, in body-composition sub-studies.
– Tolerability profile consistent with the incretin class, with gastrointestinal events most commonly reported in studies (e.g., nausea, diarrhoea, and constipation).

KLOW is ideal for body transformation protocols because it is a bioengineered blend for systemic support, combining four peptides with complementary functions in body recomposition, recovery, and inflammatory modulation.
KPV: modulation of inflammatory pathways (inhibition of NF-κB).
BPC-157: support for repair processes and angiogenesis.
TB-500: associated with cell migration and tissue recovery.
GHK-Cu: modulation of gene expression linked to the extracellular matrix and cellular recovery.
Together, KLOW was designed to promote a more stable biological environment during phases of high metabolic demand, reducing inflammatory “noise” and supporting consistency in body recomposition.

Key Benefits
– Helps reduce inflammation that can compromise results
– Supports body recovery, including tissues and performance
– Supports gut function and absorption, which underpin process consistency
– Promotes a “cleaner” metabolic environment during recomposition
– Greater resilience and energy throughout the protocol

GLOW 70 is the “finishing touch for those who are already lean” — a blend developed for the post–body transformation phase, focused on improving skin quality, firmness, and density, reducing the appearance of “loose/empty skin” and promoting a more even, rejuvenated look.

Its action is centred on remodelling the Extracellular Matrix (ECM): high-concentration GHK-Cu is associated with modulation of gene expression linked to collagen and elastin; TB-500 with cell migration and skin renewal; and BPC-157 with support for microcirculation and the reparative response.
In well-designed protocols, the result is an aesthetic finish with greater structure, elasticity, and radiance.

Key Benefits
– Firmer, more radiant skin
– Visibly more youthful appearance
– Restored elasticity (a “more filled” skin feel)
– proved dermal density and a more even texture